NIAID/NIH Recognizes the Potency of UB-421 against Multi-Drug Resistant HIV and Receives the FDA Approval to Conduct a Phase II Clinical Trial with UB-421

United BioPharma announced that the US FDA has approved a Phase II clinical trial IND submitted by the US National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH).